What is the recommended protocol for withdrawing sertraline (selective serotonin reuptake inhibitor - SSRI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 2, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Sertraline Withdrawal Protocol

Sertraline should be tapered gradually over a minimum of 6-10 weeks for patients on long-term therapy, reducing the dose by 25-50 mg every 1-2 weeks, with slower tapers extending over several months for patients who have been on treatment for more than 4-12 months. 1, 2

Why Gradual Tapering is Essential

Abrupt discontinuation of sertraline causes withdrawal syndrome in a significant proportion of patients, with symptoms typically emerging within 24-48 hours and persisting for 2-3 weeks. 3, 4 The syndrome includes:

  • Somatic symptoms: dizziness, vertigo, sensory disturbances (paresthesias), nausea, fatigue, myalgias, flu-like symptoms, and sleep disturbances 5, 4, 6
  • Psychological symptoms: anxiety, irritability, crying spells, confusion, vivid dreams, and mood changes 5, 4, 6

Sertraline, despite having a moderate half-life of approximately 26 hours, still produces withdrawal symptoms that require gradual tapering. 6, 7 Research demonstrates that 17.2% of patients on shorter half-life SSRIs experience withdrawal symptoms even with slow tapers. 6

Recommended Tapering Schedule

For Standard Long-Term Therapy (>3 months)

Start with 25-50 mg dose reductions every 1-2 weeks, monitoring closely for withdrawal symptoms at each step. 1, 2 For example, if a patient is on sertraline 150 mg:

  • Week 0-2: 150 mg → 100-125 mg 2
  • Week 2-4: 100-125 mg → 75-100 mg 2
  • Week 4-6: 75-100 mg → 50 mg 2
  • Week 6-8: 50 mg → 25 mg 2
  • Week 8-10: 25 mg → discontinue 2

For Extended Long-Term Therapy (>12 months) or High-Risk Patients

Slower tapers extending over several months are necessary, potentially using 10% reductions of the current dose at each step rather than fixed mg amounts. 1, 8 This hyperbolic tapering approach reduces the biological effect at serotonin transporters in a more linear manner, minimizing withdrawal symptoms. 8

High-risk patients requiring especially slow tapers include: 1

  • Those with previous severe withdrawal symptoms
  • Patients with comorbid anxiety disorders
  • Those on treatment duration >12 months
  • Patients with history of poor medication compliance

Managing Withdrawal Symptoms During Taper

If moderate to severe withdrawal symptoms emerge, immediately reinstitute the previous dose and hold for an additional 1-2 weeks before attempting further reduction. 1 Do not push through severe symptoms.

For mild symptoms: Reassure the patient that symptoms are transient and typically resolve within 2-3 weeks. 5, 4

For severe or intolerable symptoms: Resume the previously prescribed dose, then decrease at a more gradual rate (e.g., 10% reductions instead of 25-50 mg reductions). 1, 2

Critical Monitoring Requirements

Establish weekly contact (phone or in-person) during the first month of tapering, then monthly thereafter until complete discontinuation. 9 Monitor specifically for:

  • Withdrawal symptoms: dizziness, sensory disturbances, mood changes 2
  • Return of original psychiatric symptoms: distinguish from withdrawal 1
  • Suicidal ideation: particularly in younger patients 1

Before initiating taper, establish a collaborative plan that includes clear explanation of why gradual tapering is necessary, discussion of potential withdrawal symptoms, and agreement on the taper schedule. 1

Common Pitfalls to Avoid

Do NOT use rapid 2-4 week tapers as suggested in older guidelines—these show minimal benefit over abrupt discontinuation and are often not tolerated by patients on long-term therapy. 2, 8 The American College of Physicians explicitly states that 10-14 day tapers are inadequate for long-term therapy. 2

Do NOT stop at therapeutic minimum doses (50 mg for sertraline) and then abruptly discontinue—taper to much lower doses (25 mg or less) before complete cessation. 8

Do NOT mistake withdrawal symptoms for relapse of depression—this leads to unnecessary long-term medication continuation. 8, 5 Withdrawal symptoms typically begin within 24-48 hours of dose reduction, whereas relapse develops more gradually over weeks. 4

Do NOT use benzodiazepines to treat withdrawal symptoms—they are ineffective for SSRI discontinuation syndrome. 6 The only effective treatment is restarting the SSRI. 4, 6

Special Considerations

For patients switching to another antidepressant (cross-tapering), maintain sertraline at the current dose while starting the new medication at low doses, then begin gradual sertraline taper only after confirming tolerability of the new agent. 9

Patient education is paramount: Explain that withdrawal symptoms do not indicate addiction, are time-limited, and can be managed by slowing the taper. 4 Poor treatment compliance and lack of patient education are risk factors for severe withdrawal. 4

The taper rate is ultimately determined by the patient's ability to tolerate dose reductions—some patients require tapers extending over 6-12 months. 1, 8

References

Guideline

Sertraline Dosing and Administration

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Sertraline Discontinuation Syndrome Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Paroxetine withdrawal syndrome].

Annales de medecine interne, 2000

Research

Clinical management of antidepressant discontinuation.

The Journal of clinical psychiatry, 1997

Research

Serotonin reuptake inhibitor withdrawal.

Journal of clinical psychopharmacology, 1996

Guideline

Cross-Tapering from Escitalopram to Sertraline

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.